| Predictions for Biotech Data Heading to ASCO Bio Tuesday submits: Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8. He expects: AEterna Zentaris (NASDAQ:AEZS) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, of which top-line data were originally reported last November; and DiagnoCure’s (DGCRF.PK) partner Gen-Probe (GPRO) and other clinical collaborators to present two studies further supporting utility of DiagnoCure’s prostate cancer marker PCA3; and OncoGenex Pharmaceuticals (NASDAQ:OGXI) and collaborators to report final data from a 48-patient Phase 1 study testing heat shock protein 27 (Hsp27)-targeted antisense drug OGX-427; and Oncolytics Biotech (ONCY) and collaborators to report final data testing Reolysin in a Phase 2 open-label head and neck cancer trial plus two Phase 1/2 studies in lung and ovarian cancer; and Tekmira Pharmaceuticals' [TSX:TKM] partner Alnylam (ALNY) to report interim Phase 1 data from a 58-patient advanced solid tumour trial testing siRNA candidate ALN-VSP02; and YM BioSciences’ (AMEX: YMI) lead EGFr-targeted antibody drug nimotuzumab to be the subject of several clinical updates by partners.Disclosure: No positionsComplete Story » seekingalpha.com |
The Other Side of Genzyme Takeover Speculation Derek Lowe submits: In his classic Where Are the Customers' Yachts?, Fred Schwed mentions that the option market can be a good corrective when you're talking yourself into some investment idea. Take a look at it, he says, and you can see how many people are putting their own money down on the proposition that you might be wrong.Someone's doing just that with the Genzyme (GENZ) takeover speculation, according to the Wall Street Journal. Some trader opened up thousands of option contracts the other day, selling a pile of $75 October call options and opening up a January put spread between 55 and 65. I know that this is gibberish to most people who don't think about this stuff all the time, but what it means is that whoever this is doesn't think that Genzyme is going to make 75 by the end of October (or wants to be protected against the possibility that it won't), and will start to really clean up if the stock starts moving down below 55 again sometime before the end of January.Complete Story » seekingalpha.com |
Judge Holds Off on Lovenox Decision A federal judge held off a decision on whether to bar a generic version of Sanofi-Aventis SA's big-selling drug Lovenox, in a lengthy court hearing that highlighted the stakes for a new generation of copycat drugs. online.wsj.com |
Insurers Denied Coverage to 1 in 7 The four largest U.S. for-profit health insurers on average denied policies to one out of every seven applicants based on their prior medical history, according to a congressional investigation released Tuesday. online.wsj.com |
Being Thankful After the Leftovers Research suggests that being grateful for the blessings in life can help improve peoples' psychological, emotional and physical health. online.wsj.com |